J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Structured telephone support or non‐invasive telemonitoring for patients with heart failure
TL;DR: Neither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all-cause mortality or heart failure-related hospitalisations in people with chronic heart failure.
Journal ArticleDOI
Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial
Stefano Ghio,Nick Freemantle,Laura Scelsi,Alessandra Serio,Giulia Magrini,Michele Pasotti,Aparna Shankar,John G.F. Cleland,Luigi Tavazzi +8 more
TL;DR: In this article, the long-term effects of cardiac resynchronization therapy (CRT) on the reverse remodelling of the left ventricle (LV) were assessed at 3, 9, and 18 months and at the end of study (average 29 months).
Journal ArticleDOI
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
Amala A. Louis,John G.F. Cleland,Sheran Crabbe,Sarah Ford,Simon Thackray,Timothy Houghton,Andrew L. Clark +6 more
TL;DR: A summary of recent research developments relating to heart failure can be found in this article, where the authors present a review of the recent developments in heart failure and its prevention, including the use of the beta-blocker carvedilol in severe heart failure, and the CAPRICORN trial.
Journal ArticleDOI
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Marco Metra,Christian Torp-Pedersen,Karl Swedberg,John G.F. Cleland,Andrea Di Lenarda,Michel Komajda,Willem J. Remme,Beatrix Lutiger,Armin Scherhag,Mary Ann Lukas,Andrew Charlesworth,Philip A. Poole-Wilson +11 more
TL;DR: Beta-blocker dose, HR, and SBP achieved during beta- blocker therapy have independent prognostic value in heart failure.
Journal ArticleDOI
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study
Alexandre Mebazaa,Peter S. Pang,Miguel Tavares,Sean P. Collins,Alan B. Storrow,Said Laribi,Stephanie Andre,D. M. Courtney,Jennifer Hasa,Jindrich Spinar,Josep Masip,William F. Peacock,Karen Sliwa,Etienne Gayat,Gerasimos Filippatos,John G.F. Cleland,Mihai Gheorghiade +16 more
TL;DR: When sitting upright, dyspnoea in the sitting position improves rapidly and substantially in patients with AHF after administration of conventional therapy, mainly intra-venous diuretics, however, many patients remain orthopnoeic.